Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Depreciation & Amortization (CF): 2011-2024

Historic Depreciation & Amortization (CF) for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $2.3 million.

  • Mimedx Group's Depreciation & Amortization (CF) fell 1.38% to $572,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1.26%. This contributed to the annual value of $2.3 million for FY2024, which is 14.48% down from last year.
  • Mimedx Group's Depreciation & Amortization (CF) amounted to $2.3 million in FY2024, which was down 14.48% from $2.7 million recorded in FY2023.
  • Mimedx Group's 5-year Depreciation & Amortization (CF) high stood at $5.8 million for FY2020, and its period low was $2.3 million during FY2024.
  • Over the past 3 years, Mimedx Group's median Depreciation & Amortization (CF) value was $2.7 million (recorded in 2023), while the average stood at $2.8 million.
  • Data for Mimedx Group's Depreciation & Amortization (CF) shows a maximum YoY fell of 24.54% (in 2021) over the last 5 years.
  • Over the past 5 years, Mimedx Group's Depreciation & Amortization (CF) (Yearly) stood at $5.8 million in 2020, then declined by 24.54% to $4.4 million in 2021, then dropped by 23.33% to $3.3 million in 2022, then decreased by 20.33% to $2.7 million in 2023, then fell by 14.48% to $2.3 million in 2024.